Ainos Inc. (AIMD, Financial) has made significant strides in the development of its oral interferon drug platform, Veldona, particularly in the field of rare diseases. The Taiwan Food and Drug Administration (TFDA) has given the green light for clinical trials focused on human immunodeficiency virus-related oral warts. Additionally, the necessary Institutional Review Board (IRB) approvals have been secured for an upcoming study targeting Sjogren’s Syndrome.
The forthcoming trials in Taiwan will utilize Ainos' advanced formulation of Veldona, which represents a next-generation iteration of the drug. This progress marks a crucial step forward for the company in expanding the therapeutic applications of Veldona within the niche yet impactful rare disease market.
